- Home
- Products
Sotyktu (Deucravacitinib)
Sotyktu (Deucravacitinib)
- Medicine Name: Sotyktu
- Generic Name: Deucravacitinib
- Dosage Form & Strength: Tablets – 6 mg
- Manufactured By: Bristol Myers Squibb
Sotyktu is an oral tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Limitations of Use: Sotyktu is not recommended for use in combination with other potent immunosuppressants.
Recommended Dosage:
- 6 mg orally once daily, with or without food
- Do not split, chew, or crush tablets
- Evaluate for latent or active tuberculosis prior to initiation
- Ensure all age-appropriate vaccinations are up to date before starting therapy
- Not recommended for patients with severe hepatic impairment (Child-Pugh Class C)
Hypersensitivity Reactions: May cause angioedema. Discontinue if clinically significant reactions occur.
Infections: Increased risk of infections has been reported. Avoid initiating therapy in patients with active infections. Monitor for signs during and after treatment.
Tuberculosis: Reactivation of TB may occur. Consider prophylactic TB treatment in patients with past history.
Malignancies: Risk of lymphoma and other cancers. Assess risk/benefit, especially in patients with a history of malignancy.
Vaccination: Do not administer live vaccines during treatment. The efficacy of non-live vaccines has not been studied. Herpes zoster vaccination is recommended prior to initiation.
Required Documents to Import Sotyktu into India:
- Valid prescription from a licensed healthcare provider
- Diagnostic confirmation of plaque psoriasis
- Government-issued ID of the patient
Availability in India:
Sotyktu can be legally imported through the Named Patient Program for use by individuals under medical supervision. Global Rare Meds supports availability in cities including Mumbai, Delhi, Bengaluru, Chennai, Kolkata, Pune, Hyderabad, and more.
📧 info@globalraremeds.com
📞 +91-99675 15602 (Call/WhatsApp)
Global Rare Meds ensures secure and timely delivery of Sotyktu (Deucravacitinib) through certified international suppliers. Medications are dispensed via our licensed fulfillment center in Ambernath, Thane District, India.
We offer:
- Verified sourcing from the USA, Canada, Europe, and Australia
- Cold-chain handling if required
- Regulatory-compliant documentation and packaging
- Pharmacist-checked prescriptions and safety protocols
Q: What is the generic name of Sotyktu®?
A: Deucravacitinib
Q: Who manufactures Sotyktu®?
A: Bristol Myers Squibb
Q: What is Sotyktu® approved for?
A: Treatment of moderate-to-severe plaque psoriasis in adult patients eligible for systemic therapy or phototherapy
Q: Is Sotyktu® FDA-approved?
A: Yes, approved on September 9, 2022
Q: What is the standard dosage?
A: 6 mg tablet once daily by mouth
Q: What are common side effects?
A: Upper respiratory infections, acne, folliculitis, mouth ulcers, increased creatine phosphokinase, and herpes simplex
Q: What are the storage conditions?
A: Store at 20°C to 25°C (68°F to 77°F). Keep tablets in the original packaging.
Q: How much does Sotyktu® cost in India?
A: Prices vary by source and shipping destination. Contact info@globalraremeds.com or call/WhatsApp +91-99675 15602 for a quote.
Q: Can I legally purchase Sotyktu® in India?
A: Yes. Global Rare Meds facilitates compliant procurement of Sotyktu with a valid prescription under India’s drug import regulations.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
